Objective: We sought to examine the prevalence of EEG abnormalities in Smith-Lemli-Opitz syndrome (SLOS) as well as the relationship between interictal epileptiform discharges (IEDs) and within-subject variations in attentional symptom severity.
disorder. To date, direct evidence of an etiologic role of IEDs in cognitive/behavioral alterations is lacking, except in very specific instances.
The study of the relationship between IEDs and cognitive/behavioral performance in SLOS proceeded in 3 stages: (1) an examination of the pattern of occurrence of IEDs among individuals, (2) an examination of whether subjects with IEDs on any EEG differed in baseline cognitive or behavioral characteristics from subjects without IEDs, and (3) an examination of the relationship, within-subjects, of fluctuations in the occurrence of IEDs and in attentional symptom severity. To our knowledge, this is the first study examining the association between variability in both behavior and EEG findings within individuals with a developmental disability.
METHODS Participants and study design. Participants included 23 individuals with SLOS aged between 4.0 and 17.5 years (table 1) , enrolled in a double-blinded, placebocontrolled, crossover trial of the safety and efficacy of simvastatin. Diagnosis of SLOS was based on an elevated 7-dehydrocholesterol level and identification of 2 mutant alleles of the 7-dehydrocholesterol reductase gene. Exclusion criteria included age younger than 4 years or older than 18 years, weight ,10 kg, SLOS severity score 1 .30, behavioral impairments that would interfere with blood collection, and contraindications to simvastatin. All participants were receiving treatment with cholesterol supplementation before study enrollment. The sample size was based on considerations for the clinical trial.
The study was conducted between 2004 and 2009 at the inpatient NIH Clinical Center in Bethesda, MD, and at the outpatient Psychiatry Clinic at Kennedy Krieger Institute in Baltimore, MD. Study arms included two 12-month treatment blocks: (1) cholesterol plus simvastatin, and (2) cholesterol plus placebo, separated by a 2-month washout period; study visits were at 5 time points: 0, 6, 12, 20, and 26 months (see table e-1 on the Neurology ® Web site at Neurology.org). Of the 23 participants, 18 completed the trial; reasons for incompletion included noncompliance with study procedures (n 5 3), illness unrelated to study enrollment (n 5 1), and concern for statininduced myopathy (n 5 1). The full results of the clinical trial will be reported elsewhere (C.A.W., personal communication).
Standard protocol approvals, registrations, and patient consents. The study was approved by the institutional review boards of the NIH NICHD and the Office of Human Subjects Research at Johns Hopkins Medicine. Informed consent was obtained from all participants and/or their legal guardians before study enrollment. The clinical trial is registered at www. clinicaltrials.gov (NCT00064792).
EEG recording and interpretation. Routine clinical overnight EEGs (duration 5-7 hours) were performed at each study visit, using a NeuroScan system (Compumedics NeuroScan, Charlotte, NC) with typical clinical EEG recording parameters and a standard international 10-20 montage; in 19 recordings, a double-distance montage was used when the child's adverse behavior prevented the use of a full montage. Eighty-five EEGs were successfully recorded (1-5 EEGs per participant) ( Neuropsychological and behavioral measures. To categorize the severity of intellectual disability of each participant (table e-2), baseline adaptive and intellectual functioning was assessed using the Vineland Adaptive Behavior Scales Survey Form, second edition, 3 and the Stanford-Binet Intelligence Scales, fifth edition. 4 Because approximately 39% of the participants were "nonverbal," the nonverbal IQ score was used in lieu of the full-scale IQ. Nonverbal mental age equivalency, using Stanford-Binet Intelligence Scales, fifth edition, nonverbal IQ, or the visual reception subscale of the Mullen Scales of Early Learning 5 was obtained for the purposes of valid interpretation of the Autism Diagnostic Observation Schedule (ADOS) 6 and the Autism Diagnostic Interview, revised (ADI-R). 7 Overall classification of baseline autism spectrum disorder (ASD) (including both autism and pervasive development disorder not otherwise specified) group status of "ASD" or "none" was determined by an experienced psychiatrist (E.T.) for 17 of 23 participants, based on the combined results of 3 measures: (1) ADOS (ADOS-2 diagnostic algorithm), (2) ADI-R, and (3) DSM-IV-TR 8 criteria. The ADOS-2 Comparison Score and the total score of the "Social Affect" and "Restricted and Repetitive Behavior" subscales were also examined (table 1). ADI-R and ADOS data were excluded for 6 of 23 participants with nonverbal mental ages less than 24 months (table e-2).
Symptoms of inattention and hyperactivity were assessed using both "trait" and "state" measures; trait symptoms, or overall pattern of behaviors, were examined using selected baseline visit subscale t scores (table e-2) from the Conners Parent Rating Scale-Revised Long form (CPRS-R:L). 9 The CPRS-R:L is a widely used standardized assessment of ADHD and other problem behaviors in children and adolescents. Items demonstrate significant discriminant validity (p , 0.001) for DSM-IV ADHD symptom criteria. State behaviors, or those behaviors observed over the past 6 months (since the last study visit), were examined using the age-appropriate Symptom Inventory (SI). [10] [11] [12] The SIs are parent rating scales that screen for symptoms of psychiatric disorders observed in children and adolescents. Symptom severity scores for the ADHD categories (i.e., inattentive type, hyperactive/impulsive type, combined type) were obtained for each study visit. The Child Symptom Inventory-4 has significant test-retest reliability (p , 0.0001) and high correlations with other frequently used parent rating scales for ADHD. 12 Five participants (22%) were receiving medication for ADHD at various visits during the study (viz., clonidine, guanfacine, dexmethylphenidate, amphetamine salts). All neuropsychological and behavioral measures were administered at the same visits as the EEGs.
Data analysis. Data analysis was performed in 3 stages. In the first stage, binomial intraclass correlation [13] [14] [15] was used to determine whether EEGs with IEDs were clustered nonrandomly in individuals with SLOS ( figure 1 ). For the second stage, betweengroup analysis was conducted to assess "trait" trends in the "IED group" vs the "no-IED" group. For the purpose of study group placement, the IED group was defined as presence of IEDs on any EEG (n 5 13; 56.5%), or no-IED if at least 3 EEGs were successfully completed, and no IEDs were identified on any EEG (n 5 9; 39.1%). The rationale for this grouping scheme is based on previous studies demonstrating that, in individuals with epilepsy, a single EEG is typically specific but not sensitive for IEDs, while the recording of 3 or more EEGs improves sensitivity to .80%. 16, 17 Only one participant (S21) in our study had a documented history of epilepsy and antiepileptic drug (AED) treatment; oxcarbazepine (not a known spike suppressor) was initiated between the 6-and 12-month visits. Other notable histories included a questionable history of a single seizure in the remote past (S12), and teacher-reported "staring spells" (S15); neither child was diagnosed with epilepsy. A generalized linear mixed-effects model 18, 19 found no significant within-subject treatment effect (simvastatin vs placebo) on the presence of IEDs; thus, we did not stratify subsequent analyses based on treatment. Between-group analyses (IED vs no-IED) of demographics (age and sex) and baseline neuropsychological/behavioral symptoms (intellectual and language level, autistic behaviors, and inattention/hyperactivity) were performed using both the 2-tailed Student t test and Wilcoxon Mann-Whitney U exact test to satisfy assumptions regarding sample size and data distribution. Fisher exact test was used for categorical variables (table 1) .
Finally, within-subject analyses of the occurrence of IEDs and concurrent ADHD state symptoms were examined via a linear mixed-effects model. The group classification (IED/no-IED) from the prior analysis was not relevant to this step. SI ADHD severity scores (attention, hyperactivity/impulsivity, and combined type) were used as the response variables; the presence of IEDs was a fixed effect, and subject identity factor was a random effect. Each visit was treated as an independent observation, because there was no a priori assumption that ADHD severity would increase or decrease over time. Each subject served as his or her own control, and the results therefore reflect average changes in ADHD scores at visits in which the EEG revealed IEDs, vs visits for the same subject in which the EEG revealed no IEDs. Although estimated changes in mean ADHD scores, associated with presence vs absence of IEDs, are based only on those individuals who had both EEGs with and without IEDs (n 5 7), the variance estimates of ADHD scores account for and benefit from ADHD scores from all participants. Subsequent analyses examined the effect of IED as a rate (rather than a binary variable), separately for waking and N2 sleep. To assess the potential impact of other factors on ADHD severity, post hoc hierarchical models added one additional fixed-effect covariate: ADHD medication usage, age at enrollment, sex, and time (visit number). In each model, the presence of IEDs was added hierarchically as the final predictor. Observations with missing data were excluded from all models. The random effect model imposes a marginal correlation structure. No residual correlation unaccounted for by the random effects was assumed. IED topology was central-temporal (i.e., "rolandic"). IEDs were quite frequent when present: spike counts ranged from 0 to 123 spikes/100 seconds during N2 sleep (mean 6 SD 5 52 6 34), excluding one EEG in which no N2 sleep was achieved; and 0-106 spikes/100 seconds during waking (mean 6 SD 5 21 6 25), excluding one EEG that captured no waking.
RESULTS
For the first stage of analysis, binomial intraclass correlation (r 5 0.64) suggested moderately strong clustering of epileptiform EEG abnormalities within individual subjects (figure 1), thus revealing that EEGs with IEDs were not randomly distributed among all subjects.
For the second stage of analysis, we predicted that the IED group would show elevated ADHD and autistic symptoms compared with the no-IED group. As seen in table 1, there were no significant betweengroup differences in age, ADHD trait symptoms, severity of intellectual disability, verbal ability, ADI-R scores, or DSM-IV ASD diagnosis; however, the IED group demonstrated trend level increases in male predominance and in baseline autistic "state" behaviors, with all 9 individuals (100%) in the IED group receiving ADOS-2 classifications of "autism" or "ASD." Further analyses of the ADOS-2 results revealed similar trend level increases in the total score of the Social Affect and Restricted and Repetitive Behavior subscales, but no group differences in the ADOS-2 Comparison Score (table 1) were seen.
For the third stage of analyses, as predicted, the linear mixed-effects model revealed that the presence of single-visit IEDs within individuals predicted higher ADHD symptom severity (i.e., same visit SI scores) occurring over the previous 6 months, compared with visits without IEDs: combined type symptoms (p 5 0.004, x 2 1 5 8.3; mean increase 5 27%, 5.3 points; 95% confidence interval [CI] 5 1.8-8.9), hyperactive/impulsive symptoms (p 5 0.0046, x 2 1 5 8.0; mean increase 5 34%, 2.9 points; 95% CI 5 0.93-4.9), and a trend level increase in inattentive symptoms (p 5 0.068, x 2 1 5 3.3; mean increase 5 21%, 2.3 points; 95% CI 5 20.13-4.8). Figure 2 illustrates the hyperactive-impulsive results. When the binary variable of IED presence/absence was converted to a continuous variable of spike counts, spike counts were significant predictors of all ADHD severity scores (p , 0.001), although with smaller effect sizes than seen in the binary model. Controlling for ADHD medication use, age, sex, or visit did not change the results substantively. DISCUSSION Results of this study suggest that in children with relatively mild SLOS, (1) IEDs are common, but epilepsy is not; (2) EEG findings are variable from session to session, but cluster within particular individuals over serial testing; (3) there was no evidence that propensity of IEDs was significantly associated with age, sex, cognitive or language level, or overall diagnostic classification of ASD; and (4) within-subjects, the presence of IEDs at a particular visit was associated with parent reports of increased ADHD symptom severity, relative to severity reported at another visit during which no IEDs were demonstrated.
While in most clinical situations IEDs predict the presence of epilepsy with high specificity and moderate sensitivity, 20 there are particular clinical scenarios in which they are less closely associated with epilepsy. For example, rolandic spikes, the most common variety of IEDs in this cohort, are seen in specific genetic intellectual disability syndromes (Rett syndrome 21 and fragile X syndrome 22 ), but can also be associated with the pediatric syndrome of benign epilepsy with centrotemporal spikes, or occur as a normal developmental variant. 23, 24 Whereas certain classes of IEDs have a high positive predictive value (PPV) for epilepsy (e.g., temporal lobe IEDs: 91%), rolandic spikes generally have a lower PPV (estimated at 38%). 25 While 57% of our SLOS cohort had at least one EEG with IEDs (PPV 5 8%), the vast majority (22/23; 96%) did not have diagnosed epilepsy. This observation strongly suggests the use of caution when interpreting IEDs in patients with SLOS, so as to not overinterpret IEDs' ability to predict epilepsy in this population. While IEDs were not strongly correlated with epilepsy in our cohort, they did appear to have clinical relevance, demonstrated by their association with, on average, a 34% increase in hyperactive/impulsive symptom severity. Although this observation of a within-subject, serial association appears to be novel, prior results from different populations have suggested that IEDs may disrupt cognitive and behavioral function. One cross-sectional study of referrals to a neurology clinic for ADHD demonstrated a substantial rate of IEDs (20%), 26 although the prevalence estimation may have been confounded by referral bias. Research using a different time scale (secondby-second) has also demonstrated brief impairments in attention associated with individual IEDs. 27 Within-subject variability of the presence/frequency of sharp waves in other populations has been previously noted, 28 although not previously tied to cognitive variability. Few interventional data are available to establish a causal relationship between IEDs and cognitive impairment, although a pilot treatment study in benign epilepsy with centrotemporal spikes demonstrated that therapy with levetiracetam suppressed rolandic spikes and improved auditory processing ability. 29 If such a causal association were firmly established in SLOS and other developmental disorders, it may guide future clinical trials of AEDs as "spike suppressors" for the purpose of normalizing EEGs and thus improving cognition and behavior, independently of therapy to ameliorate seizures.
The relationship between IEDs and cognition in patients with ASD, but without diagnosed clinical epilepsy, is an area of current investigation. Specifically, while children with nonsyndromic ASD have an epilepsy prevalence of 20% to 35%, the prevalence of IEDs is as high as 60%. 30 Discussions are ongoing regarding potential therapeutic uses of specific AEDs to improve behavior through IED suppression, independent of seizure treatment. While our data do not address whether IED suppression would improve cognition, nor whether Plot illustrating the within-subject regression model examining the effect of presence vs absence of IEDs on hyperactivity/impulsivity severity Within-subject regression of ADHD symptoms vs presence of IEDs. SI ADHD severity score (specifically the hyperactive/impulsive type) is on the y-axis, and the x-axis indexes subject number. The magnitude of the effect of interest, i.e., within-subjects change in ADHD severity as related to presence or absence of IEDs, is estimated from ADHD severity score differences in participants who had at least one EEG with IEDs and at least one EEG without IEDs. Variance estimations, however, benefit from information from all participants. For individuals who had EEGs with and without IEDs, horizontal lines indicate mean ADHD severity scores for visits with IEDs (heavy lines) and without IEDs (thin lines). In 6 of the 7 subjects who had EEGs both with and without IEDs, the mean ADHD hyperactive/impulsive severity score was higher at visits with IEDs than at visits without IEDs. ADHD 5 attention-deficit/ hyperactivity disorder; IED 5 interictal epileptiform discharge; SI 5 Symptom Inventory.
the IEDs themselves are causal (vs correlative) in behavioral performance variations, we present the first testretest data demonstrating an association between the presence of IEDs and alterations in neuropsychological function across 6-month intervals.
Although particular individuals were more likely than others to demonstrate IEDs, this propensity was not associated with demographic or behavioral variables. Baseline data of autistic symptoms revealed no significant between-group (IED vs no-IED) differences in ASD classification according to ADI-R or DSM-IV-TR criteria, although trend-level associations were seen between presence of IED on the one hand, and ADOS-2 classification of ASD and total ADOS-2 score on the other. The clinical significance of this association is unclear, because our limited sample of individuals who had both IED on EEG and valid ADOS data did not allow for further analyses of ADOS findings; however, a more in-depth analysis of autistic features of our SLOS cohort is currently underway and will be reported elsewhere.
There are several limitations to this study. First, while this was a relatively large sample for a rare disease, our sample size is nevertheless fairly small in absolute terms. Other significant differences may emerge with larger samples in both between-group and within-subjects analyses. Lack of compliance resulted in incomplete data for several participants. In particular, incomplete sets of EEG data may have resulted in a type II error associated with misclassification of subjects as no-IED when the missing EEGs would have shown IEDs; however, this possibility is mollified somewhat by the fact that 3 EEGs have been shown to be .80% sensitive for sharp waves in individuals who have them. 16, 17 Results of behavioral measures could potentially be influenced by unreliable parent informants, although it is not expected that such bias would preferentially affect a single group. Clinician and tester bias was reduced through blinding, as IED group status was not determined until after testing was complete. Rating scales based on retrospective reviews of behavior resulted in less direct correlations between current ADHD symptoms and presence of same-day IEDs. Stronger inferences could be made from repeated measurements of same-day EEG and behavioral performance (e.g., a continuous performance task). Finally, replication of these studies in larger populations with other etiologies for developmental delay will be necessary to establish the generalizability of our finding; interventional clinical trials will be necessary to firmly establish a causal association between IEDs and fluctuations in cognitive abilities. Serial studies should examine specific behaviors that may be influenced by the presence of IEDs on EEG in SLOS (and other neurodevelopmental disorders).
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Comment: EEGs not likely helpful for behavioral assessments in Smith-Lemli-Opitz
Neurologists' interpretations that a routine EEG shows interictal epileptiform discharges (IEDs) have high variability and low sensitivity in cohorts of idiopathic epilepsies. 1 However, given the wide availability of EEG and the heterogeneous nature and observational criteria for behavioral diagnoses, identifying brain-based biomarkers such as IEDs could be helpful.
To this end, Schreiber et al. 2 present a lucid secondary analysis of data from an as-yet unpublished, 26-month clinical trial, conducted from 2004 to 2009, of the HMG CoA-reductase inhibitor simvastatin for 23 children aged 4 to 18 years with Smith-Lemli-Opitz syndrome. EEGs were performed at 6-month intervals, so participants had up to 5 EEGs (median 4). Thirteen of 22 individuals analyzed had at least one EEG with IEDs, of whom one had epilepsy (specificity 43%; positive predictive value 8%).
Did the categorical factor "presence of IEDs on any EEG" indicate worse behavioral problems? Univariate comparison between the group with any IEDs (n 5 13, 77% male, mean age 7 years) and the group with no IEDs (n 5 9, 33% male, mean age 9 years) across 20 factors and behavioral scores suggested worse autism (uncorrected p 5 0.07) but not attention-deficit/hyperactivity disorder (ADHD) scores in the any-IED group. However, the baseline group differences and decisions about multiple comparisons support need for replication.
Within individuals, did visits with IEDs show worse behavior than visits with no IEDs? In the 7 individuals with some IED-positive and some IEDnegative visits, mean ADHD symptom inventory scores averaged 27% higher on the IED-positive visits (linear mixed-effects model p 5 0.004). However, 85 EEGs were done as part of this study. Given the clustering of EEG results within subjects, the number needed to test in clinical practice would be quite high.
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